From Cato Today <[email protected]>
Subject Limited Government During a Pandemic
Date March 24, 2020 11:13 AM
  Links have been removed from this email. Learn more in the FAQ.
  Links have been removed from this email. Learn more in the FAQ.
In times of crisis targeted legislation is much more productive. Certain drugs can be prescribed regardless of FDA approval for coronavirus.

View in browser ([link removed] )

March 24, 2020

Capitol Building ([link removed] )

Targeted Legislation Limits Government Expansion ([link removed] )

Lobbyists and activists are trying to slip unrelated measures into the coronavirus emergency bill. Congress should resist those pressures and keep the bill narrow and focused.

- Keep Emergency Legislation Narrow and Focused ([link removed] )

By David Boaz

Coronavirus ([link removed] )

“Off-Label” Use of Certain Drugs Is Not Prohibited ([link removed] )

The FDA may eventually approve chloroquine, hydroxychloroquine, and other drugs currently used off‐​label for the treatment of coronavirus and other viral infection. But clinicians are not prohibited from using them right now.

- Coronavirus, Chloroquine, and "Off-label" Use ([link removed] )

By Jeffrey A. Singer

FEATURED ARTICLES

Coronavirus and Regulation ([link removed] )

Policymakers looking for ways to mitigate the supply shock from the coronavirus outbreak should start with these regulatory reform proposals from Cato’s policy journal Regulation.

Read More ([link removed] )

The Treasury's Helicopter Cop-Out ([link removed] )

Predictably, the depths of the present economic crisis have led to several calls by economists for the Fed and other central banks to ready their money choppers for a major spending‐​spree.

Read More ([link removed] )

Government Policy and the COVID-19 Pandemic ([link removed] )

The COVID-19 outbreak is serious and scary, but it should not become an excuse to ignore costs relative to benefits when thinking about government policy.

Read More ([link removed] )

Sign Up For Other Cato Newsletters ([link removed] )

SUPPORT CATO ([link removed] )

Facebook ([link removed] )

LinkedIn ([link removed] )

Twitter ([link removed] )

Instagram ([link removed] )

YouTube ([link removed] )

Cato Institute, 1000 Massachusetts Ave, NW, Washington, DC 20001, (202) 842-0200

Manage preferences ([link removed] )
Screenshot of the email generated on import

Message Analysis